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2Abstract
Over the past ten years, the global biopharmaceutical market has grown impressively, with ten over 
the top twenty worldwide high performance medical treatment sales being biologics. Thus, biotech 
R&D (research and development) sector is becoming a key leading market, with emerging revenues 
to progressively expand. Biotechnology offers considerable advantages compared to traditional 
pharmaceuticals, such as reducing side effects, targeted treatments, higher patient compliance and 
therefore more effective treatments leading to lower healthcare costs. Within this sector, smart 
nanotechnology and colloidal self-assembling systems represent pivotal tools able to modulate the 
delivery of therapeutics. A comprehensive understanding of the processes involved in the self-
assembly of the colloidal structures discussed therein is essential for the development of relevant 
biomedical applications.
In this review we report the most promising and best performing platforms for specific classes of 
bioactive molecules and related target, spanning from siRNAs, gene/plasmids, proteins/growth 
factors, small synthetic therapeutics and bioimaging probes. 
3Introduction
The application of emerging nanotechnology to biomedical and pharmaceutical research allowed 
real progresses in the development of temporal and site specific drug delivery, leading to a new 
field of research defined as nanomedicine which nowadays is one of key fields of research [1]. Such 
a breakthrough was supported by the advanced scientific knowledge and technological development 
of different types of systems, such as carbon nanomaterials (fullerenes, nanotubes) [2], polymeric 
carriers (micelles, niosomes, nanoparticles, nanogels and macrogels) and lipid-based nanosystems 
(lipid nanovesicles, cubosomes and solid lipid nanoparticles) [3]. 
The use of colloidal delivery systems proved to be an efficient approach to improve the 
bioavailability and pharmacokinetics of small therapeutic molecules; hereby we describe the most 
recent advances in the field, with particular focus on the most suitable system depending on the 
desired bioactive molecule to be delivered. 
1. Hydrogels and colloidal stuctures for drug delivery
Hydrogels can be defined as coherent systems composed by a three-dimensional fibrous network, 
usually of polymeric origins, containing a huge amount of a continuous aqueous phase which 
cannot dissolve the network due to the presence of interconnections, called crosslinks [4]. 
Interestingly, despite the remarkable amount of the aqueous phase that these systems are able to 
host (the solid network volume fraction can be lower than 1%), hydrogels show rheological-
mechanical properties closer to solids rather than to liquids [4], mimicking living tissues [5]. 
Hydrogels can be classified according to the nature of the crosslinks, their origin, composition, 
charge and configuration [6]. From a crosslinking point of view, hydrogels can be chemical or 
physical. In chemical hydrogels, crosslinks between different chains (fibers) are strong, permanent 
and punctual, due to covalent bonds. Conversely, physical hydrogels are characterized by either 
chains topological entanglements (spaghetti-like configuration, Fig. 1) or physical interactions (this 
being typical of polysaccharides such as glucans and xanthan) such as H-bonds, ionic, Coulombic, 
van der Waals, dipole-dipole and hydrophobic interactions.
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Figure 1. Representative examples of chemical and physical crosslinks occurring in hydrogels. 
Adapted from [4].
Additional junctions can occur, with long chain segments departing from the ordered junction zones 
towards further chains, generating a polymeric three-dimensional network. Physical interactions are 
often transient, with non-strong bonding points, able to lead to a network characterized by a 
constant average crosslink density (i. e. moles of crosslinks per gel unit volume) and a time 
dependent spatial distribution of crosslinks. Thus, network meshes configure as a dynamic 
equilibrium, due to chains segments size and related Brownian motions, being the average mesh 
number and dimension constant [4,7]. The formation of ordered zones is favored/hindered by 
environmental conditions such as temperature and ionic strength [8]. For instance, agarose 
undergoes a thermo-reversible gelation process occurring when hot solutions are cooled below ∼ 
40°C. In the hot state, agarose chains appear to behave as stiffened coils whereas, after cooling, a 
particularly extensive re-organization takes place, resulting in a hydrogel aggregation, at very low 
polymer concentrations (≥ 0.1% w/w) [9]. Physical crosslinks are usually associated with 
5mechanically weak gels, except for e.g., the case of alginates, where a strong physical hydrogel 
arises. Alginates are linear polymers of vegetal or bacterial origin containing β-D-mannuronic (M) 
and α-L-guluronic (G) acid [10], where the addition of different cations, such as Ca2+, Cu2+, Ba2+ 
and Sr2+, can induce gelation. These cations bind to stretches of guluronic acid residues within the 
polysaccharide chain, leading to the formation of junctions, which physically hold together the 
polysaccharide chains in a 3D continuum according to the egg-box model (see Fig. 1). Pectins are 
another outstanding example of polysaccharides leading to strong physical hydrogels, triggered by 
the presence of divalent cations, although with some differences connected to the existence of 
neutral sugars in the chains (that should hinder inter-chain association) and the methylation of some 
galactunorate residues (that do not contribute to the electrostatic ion binding).
With reference to their origin, hydrogels can be natural or synthetic. Among the plethora of natural 
hydrogels, those based on agar, collagen, chitosan, alginate, hyaluronic acid, gelatin, fibrin and 
polysaccharides (animal, vegetal and microorganisms origin [10]) are most represented [11]. 
Conversely, D,L-lactide-co-glycolide (PLGA), polyamidoamine (PAMAM), poly(caprolactone-co-
ethylethylene phosphate) (PCLEEP) and poly(N-vinyl-2-pyrrolidone) PVP can be included in the 
synthetic class.
For homopolymeric hydrogels, the network is formed towards a polymer constituted by a single 
species of monomer, whereas in copolymeric hydrogels two or more different monomer species 
compose the chains of the polymeric network. Finally, interpenetrating polymeric hydrogels (IPN) 
are made up of two (or more) independent cross-linked synthetic and/or natural polymeric chains 
[12].
Hydrogels can be categorized depending on their charge features, as nonionic (neutral), ionic 
(anionic or cationic), amphoteric electrolyte (ampholytic) containing both acidic and basic groups, 
zwitterionic (polybetaines) containing both anionic and cationic groups in each structural repeating 
unit. From a configuration perspective, they can be amorphous, semicrystalline (a mixture of 
amorphous and crystalline phases) and crystalline [6].
6Hydrogel production can be achieved by means of any technique allowing the formation of bonds 
among different polymeric chains, such as chemical reaction, ionizing radiations, physical 
interactions (e.g. entanglements and electrostatics) and crystallite formation. Moreover, hydrogels 
can be obtained thanks to polymerization techniques, including bulk, solution, and suspension 
polymerization [6]. However, when hydrogels are formed starting from a solution containing the 
polymer and hydrophilic drugs that can easily undergo denaturation such proteins, peptides and 
drugs based on nucleic acid (NABDs), an aqueous environment and room temperature are 
mandatory to perform a safe crosslinking procedure. For example, these requirements are perfectly 
accomplished by the ionic gelation of polysaccharides such as alginates and galacturonic [13]. Ionic 
gelation can also occur in the case of polycations with an anion as the crosslinker. Specifically, the 
ionic interaction between chitosan (polycation) and the trivalent negatively charged glycerol 
phosphate was shown to induce hydrogel formation [14].
Both macroscopic and micro/nanoscopic properties of hydrogels play an important role in 
biomedical applications. It has been recently demonstrated that, in three-dimensional culturing, the 
(macroscopic) viscoelastic properties of hydrogels used as substitutes of natural extracellular matrix 
(EM) can affect cells behaviour in terms of spreading, proliferation and differentiation. Chaudhuri 
and co-workers [15] demonstrated that the osteogenic differentiation of mesenchymal stem cells 
(MSCs) strictly depends on the viscoelastic properties of the alginates hydrogels used as substitute 
of EM. In detail, mesenchymal stem cells form mineralized, collagen-1-rich matrix similar to bone 
only when they are in contact with highly elastic hydrogels.
On the other hand, when hydrogels are devoted to the release of active agents, the mesh size 
distribution of the three-dimensional network (nanoscopic property) is a core characteristic. Indeed, 
it can represent the key parameter ruling the release kinetics of an embedded drug, or it can be 
essential to protect hydrogel load (drug, cells and so on) by external factors such as enzymes and 
the immune system agents as it can happen in the case of hydrogel based implantable systems. An 
7interesting example is represented by immunoisolant membranes, which serve to protect 
encapsulated pancreatic cells (aimed at the production of insulin) from antibodies [16]. 
In terms of release mechanisms, hydrogels drug depot can be controlled by physical, 
physicochemical and system related strands [17]. Swelling/shrinking processes are related to 
physical phenomena, whereas erosion, drug dissolution (recrystallization), drug transport (by 
diffusion and convection) and drug interaction throughout the matrix structure constitute the 
physicochemical phenomena. System related mechanisms depend on the initial drug distribution 
and concentration inside the hydrogel, hydrogel geometry (cylindrical, spherical, etc.) and size 
distribution in the case of polydispersed ensembles of hydrogels. 
The swelling/shrinking process occurs upon variation of external factors (temperature and pH, more 
frequently), inducing a new equilibrium condition or when the dry hydrogel is in contact with an 
aqueous environment. The above mentioned process relies on the chemical potential difference 
between the water inside and outside the hydrogel [18].
Hydrogel erosion can be ruled out by chemical and/or physical factors. Erosion can be defined as 
peripheral or heterogeneous, when it affects only hydrogel surface. On the other hand, bulk or 
homogeneous erosion involves the whole hydrogel volume [19]. Chemical erosion is due to 
hydrolytic/enzymatic degradation of polymeric chains, while physical erosion depends on chains 
disentanglement due to the hydrodynamic conditions of the external aqueous environment. 
Stability restrictions often require a hydrogels storage in the dry status. In such a case, drug release 
will begin as soon as an external aqueous fluid diffuses towards the polymeric network and a key 
step can be represented by the drug dissolution over the water permeating the network. When 
metastable bioactive molecules like polymorphs, amorphous or nano-crystalline drugs are present in 
the dry hydrogel, the dissolution process may correlate with recrystallization which leads to the 
formation of a new, more stable, drug crystallographic organization induced by the contact with the 
absorbed water [20].
8Bioactive molecule depot and mobility towards colloidal networks can be strongly affected by the 
hydrogel mesh size distribution, as well as by the drug physical and chemical interactions with the 
3D polymeric network [21]. For instance, drug adsorption/desorption phenomena may be due to 
electrostatic interactions, such as charged polypeptides and antibiotics in collagen matrices [22]. 
Further elements able to influence and drive bioactive molecule depot involve hydrogen bonds [23], 
lipophilic [24], as well as non-covalent interactions among imprinted polymeric networks and 
template molecules that need to be recognized in a physiological environment [25].
Colloidal and hydrogel frameworks are key structures for several bioactive molecule controlled 
delivery, with a specific application for Nucleic Acid based Drugs (NABDs) release.
NABDs are constituted by short sequences of either DNA or RNA, including antisense 
oligonucleotides, decoys oligonucleotides, aptamers, triple helix forming oligonucleotides, 
DNAzymes, Ribozymes, small interfering RNAs (siRNAs) and micro interfering RNAs (miRNAs) 
[10]. Despite their huge therapeutic potential towards different hyper-proliferative diseases [26], 
their daily clinic application is still very limited because of their rapid degradation by several 
enzymes, such as blood and cellular nucleases [27]. Moreover, as detailed in the next section (2.2), 
considering that both NABDs and cellular membranes are negatively charged, crossing the cellular 
membrane represents the core drawback, due to electrostatic repulsion. Thus, if delivered as naked 
NABDs, they have no chance to exploit their therapeutic activity. Delivery vectors can be divided 
into three classes, based on their size [28]: nano, micro and macro scales vectors. Nanoscale vectors 
are represented by polycationic polymers or lipids that self-assemble with NABDs to form 
polyelectrolyte complexes (poly- or lipo-plexes, respectively, as detailed in section 2). Microscale 
vectors can be outlined, for example, as hydrogels entrapping the poly- or lipo-plexes. Macroscale 
vectors are three dimensional matrices (such as hydrogels) that can host microvectors containing, in 
turn, poly- lipo-plexes to give rise to a chimeric system [29]. An outstanding example of chimeric 
system has been proposed by Knipe and co-workers [30], who dealt with the oral release of siRNA 
targeting TNF-β, an inflammatory cytokine that is a clinical target of inflammatory bowel diseases. 
9The chimeric delivery system consists of micro-gels (size < 30 µm) composed of poly(methacrylic 
acid-co-N-vinyl-2-pyrrolidone) (PMANVP) crosslinked with a trypsin – degradable peptide linker. 
PMANVP micro-gels contained siRNA-loaded polycationic nanogels (2-(diethylamino)ethyl 
metacrylate) (size ≈ 120 nm) that proved to guarantee siRNA protection and cells transfection. 
PMANVP matrix was designed to collapse around nanogels to protect them from degradation in the 
stomach (pH 2 – 4), while PMANVP swelling in the small intestine environment at pH 6 – 7.5, 
allowed matrix degradation, due to the uptake of intestinal fluids containing trypsin. Consequently, 
nano-gels could be released and internalized by cells, resulting in a considerable TNF-β knockdown 
in a murine macrophage model.
Chimeric systems can be used for the systemic delivery of NABDs too. Indeed, following injection 
administration, the NABD-vector complex is supposed to circulate towards capillaries and 
microvasculature structures (blood vessel diameter < 100 µm), cross the blood vessel wall and 
finally reach the target cells. Thus, the NABD-vector complex is required to move radially towards 
the vessel wall, by means of a margination mechanism. D’Apolito and co-workers [31] 
experimentally showed that margination is due to red blood cells and NABD-vector complexes 
interaction. The mentioned process is possible whether complexes size spans in diameter range > 1 
μm, with 3 µm vectors better marginating than 1 µm sized particles. Accordingly, nano-sized 
complexes have poor chances to get the blood wall. However, nano complexes embedding into 
micro-vectors allows the overall structure to reach blood vessel wall. Therein, nano-vectors can be 
released, for example, by micro-vectors surface or bulk erosion.
2. siRNA delivery
2.1. Small interfering RNAs
In recent years the most commonly tested NABDs have been siRNAs. These short double stranded 
RNA molecules approximately 22 nucleotides in length, are mostly of exogenous origin, being 
generated from invasive nucleic acids such as viruses and transposons [32]. With reference to the 
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mechanism of the two siRNAs filaments (Fig. 2A), mostly the antisense strand is uptaken by the 
cytoplasmic RNA-induced silencing protein complex (RISC). The antisense strand drives RISC to a 
target RNA via a perfect sequence complementarity to the target. Following binding, RISC 
mediates the degradation of the target RNA thus resulting in the downregulation of gene expression. 
It is possible to take advantage of this mechanism of action to generate siRNAs able to target RNAs 
causing disease as shown by many works [33-36]. 
Figure 2. Schematic representation of (A) siRNA cascade towards cytoplasmic RNA-induced 
silencing protein complex (RISC) and (B) siRNA metabolism throughout cellular mechanisms.
2.2. siRNA delivery problems
Despite the great siRNA therapeutic potential, their practical use is limited by their chemical nature. 
Following systemic administration, siRNAs encounter blood nucleases, which can rapidly degrade 
their nucleic acid structure (Fig. 2B). 
Moreover, siRNAs tend to be removed by the reticulo-endothelial system, by kidney filtration [37] 
and, depending on the sequence, to activate the innate immune response [38]. Additional barriers to 
siRNAs cellular uptake are represented by the vessel wall and the cellular membrane, due to the 
electrostatic repulsion between the negatively charged phosphate groups present on siRNAs and the 
negatively charged surface of cellular membranes. Moreover, cell uptake is difficult by the 
hydrophilic nature of siRNAs that does favor the crossing of the hydrophobic layer of the cell 
membranes. 
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The fraction of siRNAs that succeed crossing the cell membrane, further will face with cytosolic 
nucleases that can reduce their amount. Finally, siRNAs experience the problem of cellular 
trafficking [39]. Depending on the mechanism of cellular internalization, siRNAs can be uptaken by 
endosomes. At this stage, when confined into these intracellular vesicles, siRNAs have no chance to 
reach their targets and thus to exert any biological effect. Based on the above mentioned 
considerations, the administration of naked siRNA results in negligible therapeutic effects. 
2.3. Strategies to minimize siRNA delivery issues
To minimize the delivery issues of exogenous siRNAs, two main strategies can be employed. The 
first consists of the chemical modification of siRNA structure to make these molecules more 
resistant to degradation. The second strategy is based on the siRNA complexation with synthetic 
engineered vectors to effectively bind and protect siRNAs and to allow their delivery to the target 
cells [40]. Frequently, the two strategies are used in combination, despite some chemical 
modifications may affect siRNA effectiveness. 
The choice of the optimal delivery materials is not a trivial task [10,32,40,41], with the net 
superficial charge of the delivery carrier/siRNA complex playing a key role. Anionic and cationic 
complexes usually show good solubility/stability in the physiological environment, despite they 
exhibit some drawbacks. Anionic complexes cannot transfect cells per se, due to the electrostatic 
repulsion with the negatively charged cell membrane. Conversely, cationic complexes bind to cell 
membrane towards strong electrostatic interactions, leading to non-specific cellular uptake and cell 
toxicity if the positive charge is not optimal [42]. On the other hand, neutral complexes tend to 
associate in the physiological environment, resulting in a limited solubility. Thus, the development 
of optimal delivery carriers requires a careful evaluation of different parameters such as the surface 
charge density, within a multidisciplinary team.
Besides providing for siRNA protection and targeting, the ideal delivery vector should be able to 
allow efficient extravasation of the siRNA. This feature is crucial for siRNA-vector complexes 
systemic administration. Therein, the size of 
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siRNA-vector complexes plays a relevant role, as above mentioned for NABDs. It has been recently 
showed that particles in the 1-3 µm diameter range [31] tend to localize closer to the endothelial 
layer (margination effect) of the vessel, compared to smaller particles. Thus, 1-3 µm particles 
localize closer to the vessel fenestration, being more susceptible to extravasation compared to 
smaller particles, which, alternatively, tend to localize in the middle of the vessel. Despite this 
advantage, it should be considered that particles bigger than 0.2 µm are readily scavenged non-
specifically by monocytes and the reticuloendothelial system, thus not be efficiently uptaken by 
cells [43,44]. A possible solution may rely on the preparation of microparticles able to undergo a 
disassembly, upon extravasation, originating nano-metric particles. As previously introduced, the 
preparation of micro-sized delivery systems containing nano-metric particles can be included within 
the class of delivery strategies known as “chimeric systems” [28,45]. This approach present a dual 
advantage: on one side, micro-particles are easy to handle, to produce on large scale and to store, 
whereas on the other hand, nanostructures are characterized by an extremely high surface/volume 
ratio, with a valuable drug payload efficiency. Polycationic polymers and lipids are most commonly 
employed to form nanoscale vectors. On the other hand, microscale vectors entrapping nanoscale 
vectors usually consist of two/three dimensional scaffolds or matrices mainly made by polymers.
The following sections will focus on the presentation of strategies most commonly used to prepare 
nanoscale vectors, i.e. lipid and polymers nanoparticles [46-50]. 
2.3.1 Lipidic nanoparticles
Lipid-based nanoparticles (LNPs) have been extensively used as delivery systems for drugs and 
siRNAs, showing promising results both in vivo and in vitro. LNPs have appropriate delivery 
characteristics as their structure mimics cellular membranes, thus enhance the fusion with the target 
cell. Moreover, LNPs can be easily loaded with several cargo molecules. 
2.3.1.1 Liposomes
Liposomes are spherical self-assembled vesicles, deriving from synthetic or natural phospholipids 
containing aqueous compartments (Fig. 3A). 
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The polar heads of phospholipids interact with the hydrophilic environment thus stabilizing lipids 
structure; in contrast, the long phospholipid chains interact each other, forming lipid layers in 
aqueous solution. Liposomes can be structured as unilamellar or multilamellar lipid bilayers. Due to 
the amphiphilic nature of phospholipids, these molecules can generate hydrophilic and hydrophobic 
compartments in the same system, thus allow for both hydrophobic and hydrophilic molecules 
(siRNA) hosting. Liposomes can also accumulate into tumours, present a low immunogenicity and 
are biodegradable [51]. 
2.3.1.2 Cationic liposomes 
Positively charged (cationic) liposomes are most frequently used for siRNA delivery. They can 
electrostatically interact with the negatively charged siRNAs and allow an efficient molecule 
loading [41,52]. Additionally, cationic liposomes can easily interact with the negatively charged 
cell membrane. Sometimes, to further improve the ability to integrate with cell membrane, they are 
added with non-cationic lipids, such as DOPE (dioleoylphosphatidylethanolamine) and DSPC (1,2-
Distearoyl-sn-glycero-3-phosphocholine). The positive surface charge is favourable for siRNA 
binding, but it can cause the side interaction with negatively charged serum protein such as 
albumin. In such a case, the negatively charged serum protein can displace siRNA from the 
positively charged liposome, thus significantly reducing the amount of siRNA delivered to the 
target tissue. The modification of liposomes with the neutral lipids such as cholesterol can 
contribute to overcome this limitation [53]. Moreover, cholesterol can be used also to bind other 
molecules such as polyethylene glycol (PEG), a polymer able to improve the delivery properties 
both in vitro and in vivo [51].
There are different types of cationic liposomes for siRNA delivery, such as monovalent cationic 
liposomes and multivalent cationic liposomes. For instance, N-[1-(2,3-dioleyloxy) propyl]-N,N,N-
trimethylammonium chloride (DOTMA), 1,2-bis(oleoyloxy)-3-(trimethylammonio)-propane 
(DOTAP) and 3β-[N-(N'N'-dimethylaminoethane) carbamoyl]cholesterol (DC-Chol) are 
monovalent cationic lipids, characterized by a high in vitro transfection efficiency [54].
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Multivalent cationic lipids (MCLs), synthetized from monovalent cationic lipids, exhibit an 
increased positive charge compared to monovalent cationic lipids. However, they tend to be more 
toxic than monovalent cationic lipids [55]. A widely used MCL transfection agent is Lipofectamine 
(2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-pro-paneammonium 
trifluoroacetate and dioleoyl-hosphatidylethanolamine in ratio 3:1 (DOSPA/DOPE 3/1)), which 
contains the multivalent cationic lipid DOSPA. This mixture of lipids forms multilayers structures 
with the siRNA being embedded between adjacent lipid bilayers [56]. Lipofectamine can efficiently 
deliver siRNAs to a broad range of cells, although they exert a significant unspecific cell toxicity. 
For example, siRNAs directed against the mRNAs of the cell cycle promoting genes cyclin E and 
E2F resulted in a relevant inhibition of smooth muscle cells (SMC) proliferation. As SMC aberrant 
proliferation is a key event in many coronary artery diseases [44,57], the mentioned approach has 
the potential to minimize this pathological event. Per se, the cationic liposome-mediated delivery of 
siRNAs to the coronary wall is not sufficient to guarantee an effective delivery. In this case, the 
delivery of siRNA-cationic liposomes entrapped into gel matrix has been proposed, in order to 
prevent the rapid wash out of siRNA complexes due to blood flow [58]. 
2.3.1.3 Stable nucleic acid lipid particles (SNALPs)
Recently, stable nucleic acid lipid particles (SNALPs) have been developed for siRNAs delivery 
(Fig. 3B) [41]. SNAPLs are constituted by a lipid bilayer containing the ionisable cationic lipid 1,2-
dilinoleyloxy-3-dimethylaminopropane (DLinDMA) or  2,2-dilinoleyl-4-(2-dimethylaminoethyl)-
[1,3]-dioxolane (DLin-KC2-DMA) in the inner part, to allow the binding with siRNAs. Moreover, 
they contain PEG, which can stabilize the complex and a neutral lipid, like DSPC  or cholesterol, 
which enhances the endosomal escape of the SNALP/siRNA complex [59]. Thus, whereas the inner 
part of SNALPs is hydrophilic and allows the electrostatic binding with siRNAs, the surface charge 
is nearly neutral. Appropriate modifications in SNALPs, for example in the type and ratio of the 
different components, can extend the circulation time and minimize complement system activation 
[51].
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SNALPs delivery systems were for example used to encapsulate a COP9 Signalosome Subunit 5 
(CSN5) siRNA [60]. CSN5 is the catalytic center of the COP9 Signalosome that is involved in the 
control of proteolysis via the ubiquitin proteasoma pathway. CSN5 seems also to act as 
transcriptional coactivator for MYC and TGFβ1, gene products involved in the control of 
proliferation, apoptotic cell death and hepatocellular carcinoma (HCC) progression. This delivery 
system significantly inhibited tumor growth in an orthotopic mouse model of HCC [60].
2.3.1.4 Lipidoid nanoparticles 
Lipidoid nanoparticles are made up of synthetic lipids obtained by the chemical combination of 
alkyl-amines with alkyl-acrylates containing carbon chain tail of variable length [61] (Fig. 3C). The 
particles containing the lipidoid have a polar and ionisable core, surrounded by hydrophobic carbon 
tails. The particles can also contain cholesterol and PEG, two types of molecules that can enhance 
particles stability and delivery efficiency [56]. In addition, their easy synthetic protocol allows the 
production of a considerable amount of different particles, which can be tailored to any different 
delivery purpose. For example, a siRNA embedded into lipidoid-based nanoparticles was used to 
downregulate β1 and αν integrin subunits in the hepatocytes of a xenograft mice model of HCC 
[62]. β1 and αν integrins are relevant extracellular matrix receptors involved in many cellular 
processes. Moreover, they play critical biological roles both in normal liver and in HCC tumor 
cells. Integrin silencing had, as major outcome, an extended morbidity-free survival of HCC tumor-
bearing mice[62]. 
A) Liposome  B) SNALP
C) Lipidoid
 D) Solid Lipid Nanoparticle
Ionisable cationic lipid
Neutral lipid
PEG 
Lipid core
siRNA
Nautral/Anionic /Cationic
lipid
Cholesterol
Synthetic lipid
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Figure 3. Schematic representation of the main nanoscale vectors: (A) liposomes, (B) stable nucleic 
acid lipid particles (SNALPs), (C) lipidoids and (D) solid lipid nanoparticles.
2.3.1.5 Solid-lipid nanoparticles
Solid-lipid nanoparticles (SLN) are novel siRNAs carriers derived from nano-emulsions where the 
oil emulsion component is replaced by a solid lipid dispersed in a surfactant solution (Fig. 3D). The 
loaded molecules are incorporated in the solid lipophilic matrix. SLN, solid at room temperature, 
are stable, non-cytotoxic, present a large surface area and can efficiently protect the encapsulated 
molecules [63]. However, they present some disadvantages such as the low molecules loading 
capacity and the possible expulsion of the incorporated molecules during storage. The chemical 
nature of the solid-lipid matrix determines the loading capacity, as well as the type of molecule to 
be loaded [64]. SLN usually contain a combination of triglycerides, partial glycerides, fatty acids, 
steroids and waxes. To decrease cytotoxicity and immune responses, SLN can be prepared using 
physiological lipids present in the natural low density lipoprotein (LDL) such as cholesteryl ester, 
triglyceride, cholesterol, DOPE, and DC-cholesterol [65]. Lipids found in the natural high-density 
lipoproteins (HDL) represent an alternative. Overall, chemical modifications are required to allow 
the incorporation of the hydrophilic siRNA [66]. An example of siRNA delivery by SLN has been 
reported by Jin J. et al. [67]. Considering that c-mesenchymal-epithelial transition (c-MET) is a 
signaling receptor for hepatocyte growth factor, SLN were reconstituted from natural components 
of protein-free LDL and further conjugated to PEGylated c-Met siRNA. Inappropriate c-Met 
activation relates to different form of human tumours including glioblastomas (GBMs). The latter is 
the most frequent and malignant form of brain tumor, with limited treatment options due to the 
blood-brain barrier. In orthotopic U-87MG xenograft tumour model of GBM, intravenous 
administration of the complex significantly inhibited c-Met expression and suppressed tumour 
growth. Notably, no major signs of systemic toxicity were observed in mice. 
2.3.2 Polymers 
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Polymers are solid and biodegradable molecules widely employed for siRNA delivery. Many 
different polymers have been tested so far, such as Chitosan (CH), Polyethylenimine (PEI), PEG, 
α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide and Inulin-derived polymers. 
CH is a polymer characterized by low toxicity, high biocompatibility and biodegradability [10]. CH 
is derived from chitin, has a carbohydrate backbone characterized by two types of repeating 
residues, 2-amino-2-deoxy-glucose (glucosamine) and 2-N-acetyl-2-deoxy-glucose (N-
glucosamine), linked by (1-4)-β-glycosidic linkage. Furthermore, CH has a positive charge, due to 
the presence of positively charged amino groups present in its structure, thus, it can easily and 
efficiently bind negatively charged molecules such as siRNAs. On the other hand, CH has some 
disadvantages such as the low transfection efficiency and low solubility, which can be avoided via 
the conjugation with other molecules such as PEI, PEG, Poly (amidoamine) (PAMAM) dendrimers. 
As an alternative, CH physicochemical and biological properties can be improved by modulating 
the deacetylation rate and/or modifying the molecular weight [68].
PEI contains repeating units composed of an amine group and two aliphatic CH2-CH2 spacers. It 
can exist both in linear and branched forms. It is one of the most used cationic polymers, even 
though it tends to be more toxic than natural polymers [69]. Usually, PEI with high molecular 
weight has higher cytotoxicity compared to low molecular weight PEI, despite its transfection 
effectiveness. To decrease toxicity, PEI can undergo chemical modifications, such as the addition of 
hydrophilic and hydrophobic segments or cell/tissue-specific ligands [70]. As previously described 
for CH, PEI easily binds negatively charged molecule such as siRNAs. Moreover, PEI favours 
siRNA escape from endosomes, thanks to its “proton sponge effect” [71]. Finally, liposome coating 
with PEI results in an increased liposomes circulatory time [72], thus improving systemic delivery. 
PEG is a polymer of ethylene oxide monomers considered to be non-toxic and safe [73,74]. It is 
widely used because of its solubility in aqueous environment and organic solvents. PEG addition 
(PEGylation) to deliver particles reduces toxicity and stabilizes the particles, as it is the case of 
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PEGylated liposomes where PEG is added into the liposomal bilayer [75]. PEG is also used to bind 
specific ligands to be fixed on the liposome surface [76]. 
For instance, a copolymer based on α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA) bearing 
positively chargeable side oligochains, with diethylamino ethyl methacrylate (DEAEMA) as 
monomer has been developed [77]. The PHEA-DEAEMA polymer was able to efficiently forming 
complexes with siRNA, demonstrated stability in liquid fluids and protected siRNA without being 
significantly cytotoxic in the HCC cell line HuH-7. The copolymer was loaded with an anti E2F1 
siRNA and tested in JHH6. E2F1 is a transcription factor promoting cell proliferation that plays an 
important role in the growth of HCC cells [26]. A significant down regulation of JHH6 cell growth 
was observed, in addition to a reduction in siRNA target.
As an alternative polymer for HCC cell delivery, a siRNA delivery system based on inulin (Inu) 
was reported. This is an abundant and natural polysaccharide functionalized for the specific 
requirements of siRNA delivery by conjugation with diethylenetriamine (DETA) residues (Inu-
DETA) [78]. Inu-DETA copolymers can effectively bind siRNAs, are highly biocompatible and, in 
the HCC cell line JHH6, can effectively deliver functional siRNAs. The Inu-DETA particles loaded 
with a siRNA anti E2F1 [26], effectively reduced the levels of E2F1 and the proliferation of JHH6. 
Moreover, the uptake and trafficking mechanisms, mainly based on micropinocytosis and clatrin 
mediated endocytosis, allowed a triggered release of siRNA within the cytoplasm of JHH6.
The above mentioned examples clearly indicate how cationic copolymers can bind siRNAs via 
electrostatic interaction, thus forming complexes able to promote cellular uptake and significantly 
improve the half-life. However, polymers can be also used in the form of micelles for delivery 
purposes. Micelles are spherical structures containing simple units (unimers) oriented with the 
hydrophobic tail towards the inner part of the micelles and the hydrophilic heads towards the 
external shell (Fig. 4). Unimers can be generated conjugating cationic polymers with stearic acid 
(SA), a saturated fatty acid with an 18-carbon chain. For example, CH polymer does not self-
assembly into micelles; nevertheless, following the conjugation with stearic acid (SA), CH polymer 
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can form micelles. This example indicates the great plasticity of polymers and their derivatives to 
prepare siRNA delivery systems [79]. Other example of cationic polymer able to form micelles in 
solution is PEG and poly(propylene sulfide) [80,81].
Hydrophilic shell
Hydrophobic core
Polymeric micelle
Figure 4. Schematic representation of a polymeric micelle.
3. Plasmid, gene and probiotic delivery
Considering drug-based treatments are limited to treat symptoms, gene delivery emerged as a very 
promising method for the treatment (or elimination) of the causes associated to a broad range of 
diseases related to genetic factors [82]. This approach relies on the effective delivery and transfer of 
genes into specific cells to alter the expression of the existing ones. Theoretically, it should either 
cure the disease or, at least, slowdown its progression [82]. There are two main components in the 
system: the carrier (i. e. gene delivery vector) and the therapeutic agent (i. e. genetic material). The 
delivery system should be able to carry, protect and delivery the genes in a safe and effective mode 
to a wide range of different cells [83]. Although viral based vectors are extremely efficient carriers 
to deliver genes, several drawbacks associated to their high cost, difficulties in large scale 
production and safety issues (e.g immunogenicity, tumorigenic mutations) have driven the attention 
to other technological alternatives. In this context, during the last decades, a lot of attention has 
been paid to the development of efficient non-viral vectors for gene delivery. Despite the low 
efficiency compared to viral vectors, these systems present several important advantages, such as 
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low immunogenicity, absence of endogenous virus recombination, low production cost, easy 
implementation in large scale [84,85].
As previously discussed, within the non-viral systems class, cationic polymers have received a 
growing interest due to the possibility to easily tune their structure and characteristics (e.g 
molecular weight and composition) in order to enhance the performance of the gene delivery 
system [86]. The positive charges of the cationic polymers interact electrostatically with the 
negative charges of the gene material, leading to the formation of complexes known as polyplexes. 
Since the pioneer work of Vaheri and Pagamo, in 1965, that proposed the use of dextran 
functionalized with diethylaminoethyl groups [87], an enormous library of cationic polymers have 
been suggested for gene delivery, such as chitosan [88,89], poly(L-Lysine) (PLL) [90], 
poly(ethylenimine) (PEI) [91], poly [(2-dimethylamino) ethyl methacrylate] (PDMAEMA) [92] and 
poly(β-amino ester) (PβAE) [93]. Despite branched PEI [91] (Mw=25000g.mol-1) has been 
considered as the “gold standard” due to the high transfection efficiency, its high toxicity seriously 
compromises its use [94].
Figure 5. Schematic examples of cationic polymers used as nonviral gene delivery vectors
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Generically, two main problems are associated to the polymer-based systems: minor efficiency due 
to the deficient capacity to overcome some extra- and intracellular gene delivery obstacles (e.g 
diffusion to the endothelial membrane, endosomal escape, unpacking among others); and 
cytotoxicity [95]. These issues have been mitigated using different approaches that include: the use 
of poly(ethylene glycol) (PEG); introduction of hydrophobic segments [95]; and the 
functionalization of polymers with moieties such as sugar molecules, antibodies, growth factors, 
etc. [85].
Despite the remarkable advances registered over the last decades on gene therapy, the levels of 
efficiency are generally very unsatisfactory to turn their clinical usage a routine. One promising 
approach to overcome this limitation involves the use of stimuli-responsive polymers that can 
change their physico-chemical characteristics upon the application of a specific stimulus. In the 
gene therapy area, these stimuli can be endogenous like enzyme concentration, pH, redox potential, 
or exogenous such as temperature, light and ultrasounds. The remarkable feature of this class of 
polymers relies on the possibility to rationally adapt the physical/chemical characteristics of 
polyplexes during their path to maximize their efficiency. The binding capability of the cationic 
segment should be high to afford dense and stable polyplex, while during the unpacking step 
weaker bindings are required [96,97]. Therefore, the use of stimuli-responsive polymers can be a 
very effective approach to tailor the properties of polyplexes in the different environments both 
outside and inside the cell. Aiming to explore the potential of these smart systems, several carriers 
have been used in gene therapy [98-100]. PDMAEMA is a thermoresponsive and pH-responsive 
polymer, being one of the most used systems in gene delivery, able to easily complex with DNA 
[92].
Reversible Deactivation Radical Polymerization (RDRP) methods brought an outstanding toolbox 
of techniques that allows to synthesize tailor-made polymers with controlled composition, 
architecture, molecular weight and active chain-end functional groups [101]. Advances on “click” 
chemistry techniques [102] as 1,3-dipolar azide-alkyne cycloaddition (CuAAC) [103] and/or thiol-
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ene [104] reactions has opened important routes to the synthesis of novel block copolymers and in 
the functionalization with different moieties (e.g proteins, sugars) to well-defined polymer 
backbone.
Nowadays, it is possible to establish precise structure/properties relationships for the different 
polymers due to the ability to control their composition, structure, and functionality. Atom Transfer 
Radical Polymerization (ATRP) [101,105] and RAFT (Reversible Addition Fragmentation 
Transfer) [106-108] are the most used ones to develop block copolymers for gene delivery. Several 
recent reviews have highlighted the important progresses achieved with these two advanced 
polymerization techniques in biomedical applications and gene delivery [109,110]. Controlled 
molecular architectures in terms of chain topology [101,106] (cycles, stars, combs, brushes), 
composition [101,106] (block, graft, alternating, gradient copolymers), and functionality are now 
easily accessible for most type of monomers used to afford stimuli-responsive structures. Star 
polymers, due to the higher ability of forming spherical polyplexes, which facilitates the 
internalization in the cell, have received particular attention [111]. Indeed, several contributions 
have shown promising results for stars regarding transfection efficiency when compared to their 
linear or randomly branched counterparts [112-114].
The simultaneous development of the polymer synthesis strategies over the next years will allow 
the preparation of new block copolymers with innovative sequential addition of new monomers. 
Consequently, it can be easily envisaged that there will be the appearance of the new cationic block 
copolymers rationally designed to overcome the aforementioned limitations (e.g biological barriers) 
leading to broad use of non-viral vectors in clinical practice. 
Surfactants, such as polymers, are excellent candidates for non-viral methods in gene delivery. As 
previously discussed, depending on surfactant architecture, they can self-assembly into different 
structures and work as efficient nano-compartments for gene delivery [115]. For this purpose, many 
synthetic surfactants or lipids have been designed to increase the performance of cellular uptake, 
transfection efficiency [116] and to enhance the solubility of hydrophobic molecules, making them 
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suitable for parenteral administration. An extensive number of contributions encompassing the 
advantages of surfactant based gene delivery systems is available in the literature [117-122]. 
Surfactant based nanoparticles are already been used to treat genetic and acquired disorders [123] 
due to their demonstrated high ability to condense and deliver nucleic acid molecules [124]. As 
mentioned in the previous section, the stabilization of the vectors composed of surfactant or lipid 
aggregates can be achieved by the addition of different additives such as cholesterol to increase the 
packing of phospholipid [125,126], or polyethylene glycol (PEG) to protect nanoparticles from the 
immune system [127].
A large range of reports suggests the use of cationic surfactants as vectors for the delivery of 
nucleic acids [124,128,129]. Their success is related to easy synthetic pathways and to an efficient 
condensation and delivery of anionic nucleic acids through electrostatic interactions. 
The cellular uptake of the nucleic acid-cationic surfactant complexes is driven by the disruption of 
the endosomal membrane due to the ion pair of the cationic surfactant and anionic lipids within the 
endosome membrane [130]. Regarding the structure, the complexes of the cationic surfactants and 
anionic phospholipids are usually arranged as inverted hexagonal phases, which apparently 
facilitates the release of the plasmid from the endosome into the cytoplasm [130].
Gemini are another class of very promising type surfactants that has been highly effective in 
delivering genetic material to cells. These systems show a very low critical micelle concentration 
which allows the use of less surfactant to achieve the same encapsulation capability [115].
Polymers and surfactants are able to encapsulate genes and drugs, as well as further cargo of 
interest for the treatment of different diseases or health problems. There have been considerable 
efforts in understanding and proving beneficial effects via the use of probiotic bacteria for different 
types of health issues ranging from gastric diseases to atopic dermatitis [131]. Probiotics are living 
microorganisms giving beneficial health effects to the host by replenishing natural gastrointestinal 
microbiota. The effectiveness of probiotics intake in some clinical cases is already recognized e.g. 
in acute gastroenteritis [132]. An estimation of about 1014 viable probiotic cells to potentially 
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harmful bacteria harbor the gastrointestinal tract of an adult and their balance is strictly depended 
on the diet of the host, medication intake, hygiene habits and diseased state [133]. Recent evidences 
highlight the remarkable role played by the gut microbiota in the predisposition to different disease 
phenotypes, which are often followed by dysbiosis, and are a major public health concern, e.g. 
obesity, diabetes and intestinal syndromes [134-136]. In this context, probiotics play a key role in 
the modification of the gene expressions, which are involved in immunomodulation, nutrient 
absorption, suppression of pathogens, energy metabolism and intestinal barrier function such as 
stimulation of epithelial cell proliferation or induction of mucin secretion [131,137-139].
The positive health benefits provided by these probiotic agents are essentially strain- and disease-
dependent. Moreover, designing a delivery vehicle capable to overcome the physiological variations 
(i.e. temperature, pH, ionic strength, etc) with an efficient approach and without any harmful effect 
to the cells and the tissues is a challenging task. As previously discussed for the gene delivery, 
several (but rather similar) barriers can delay or prevent the delivery of probiotic bacteria in a safe 
and effective fashion. Probiotics are often administered orally and, in such case, the cells are 
primarily microencapsulated in order to protect them from the harsh conditions of the 
gastrointestinal passage, i.e. low pH, presence of bile salts and enzymes. The microcapsules are 
usually formed by extrusion, emulsion, spray- and freeze-drying [140,141]. Polysaccharides 
(alginate, chitosan, gellan and xanthan gums) and milk proteins are among the most commonly used 
encapsulating agents [142]. From a formulation point of view, alginate-based materials are by far 
the most explored due to their biocompatibility, biodegradability, very good cytocompatibility and 
mucoadhesive properties. Nevertheless, new systems which can exhibit a wide variety of “smart” 
responses according to the changes in the surrounding physiological parameters are being used for 
the encapsulation and delivery of probiotics [143]. As in the gene delivey, it is possible to have, for 
instance, pH- or thermo-sensitive systems with delivery triggered by precise changes on those 
parameters [144]. As mentioned in previous sections, among the many based systems developed, 
high focus has been given to sugar-based biopolymers for biocompatibility and availability reasons 
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[145]. The use of new tailor-made polymers with smart responses (for instance, using the 
aforementioned RDRP methods) for probiotic delivery emerges as a promising field to be explored 
in the future soon which will definitely generalize the use of probiotics in the treatment of different 
health issues. 
4. Proteins and growth factor delivery
Smart biomaterial approach is one of the fastest growing segments for the treatment of high impact 
diseases, such as cancers, dietary-related disorders, ischemic diseases and dramatic inflammatory 
responses. It is set to expand over the near future, fuelled mainly by the unmet requirements from 
the market for less invasive and more successful treatments, in particular in the key areas of 
inflammatory pathological conditions. The convenience and home use appeal for patients is the 
main driving factor of this industrial branch.
In this context, the most high impact cause of death and/or disability in developed countries refers 
to enzyme and protein disorders and related consequences [146,147]. Currently, affected patients 
cannot rely on a wide variety of surgical and medical options; this condition involves an urgent 
need of possible treatment alternatives, with a main challenge lying in the decrease of side effects 
and specific tailoring of the therapeutic approach. In detail, a promising strategy concerns the study 
of key pathological signalling mechanisms and related pathways involved in the switch control 
between normal and aberrant conditions. The rationale behind such an innovative perspective is on 
stage for the development of more effective chances to therapeutically tune the inflammatory 
pathways. An important target disorder where inflammatory processes are actively incorporated 
deals with cancers: therein, biosensing approaches, such as tuning and silencing of protein and 
enzymatic activity, as well as regulation of small molecule signalling are clever strategies with a 
huge potential for impact of people’s daily life, towards the industrial nanobiotechnology sector 
growth. Over the years, nanotechnology has developed considerably as a result of novel 
technological discoveries, in the area of smart materials and related application. One area in 
bionanomaterials that offers great potential is represented by self-assembly approaches, thanks to 
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their easy strategy for preparation and suitability for biotech engineering tailored modification. Self-
assembly is the process of inter- and intra-molecular bonding through van der Waals forces, ionic 
interactions, H-bonding or hydrophobic interactions, which results in the formation of particularly 
formed structures, that can either form colloidal crystals or particle cluster among others. The 
intrinsic mobility of self-assembled complexes leads to ordered nanostructures upon equilibration 
between aggregated and non-aggregated states, thus providing a number of interesting properties 
such as error correction, self-healing, and high sensitivity to external stimuli. These structuring 
features are nowadays well understood and can be finely controlled in order to introduce and tune 
functional properties of self-assembled nanomaterials used for a wide range of applications.
Polymer-based self-assembled nanostructures, as well as organic nanomaterials (e. g. carbon nano-
onions [148]) have great potential as drug delivery vehicles for invasive cancers, mainly as a result 
of their good biocompatibility [149] and natural degradation/resorption pathways [150]. On the 
other hand, self-assembled hydrogels, composed of biocompatible and amphiphilic polymer 
conjugates, have been shown to exhibit prolonged circulation in blood and preferential 
accumulation when administrated either in vitro or in vivo. From a targeted responsiveness point-of-
view, cancers and aberrant conditions, demonstrated to be associated to low pH [151]. Thus, pH 
proved to be an excellent trigger for targeted cancer release carriers and further silencing of key 
pathological mechanisms therein involved. Another target involves small molecule changes in the 
cellular environment, such as Reactive Oxygen Species (ROS) [152] and formation of small 
amines/alcohol [153].
Besides, intercommunication between cells is mainly driven by growth factors, polypeptides which 
can modulate cellular behavior related to differentiation, proliferation and their ability to synthesize 
extra cellular matrix (ECM), by specifically targeting receptors on the cell surface [154]. Most 
biological processes are initiated by self-assembly reactions in the body. For example, assembly of 
amino acids to peptides to specific secondary, tertiary and quaternary structures that give rise to 
structural and functional proteins. From a material point-of-view, this naturally occurring 
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phenomenon can be recapitulated artificially through spontaneous and random assembly of 
naturally occurring proteins or with a bottom-up approach by incorporating functional sequences, 
which dictate a specific biological response. In this context, hydrogel systems have been 
successfully employed for growth factor delivery and regenerative purposes, thanks to their ability 
to ensure a controlled cell migration [155,156]. Moreover, as previously discussed, hydrogels are 
widely applied for drug delivery purposes, as they mimic the natural ECM [157,158] and allow a 
dual responsive drug release, offering the advantage of incorporation of further supramolecular 
structure, such as liposomes and further micro/nano carriers.
For instance, the peptide sequence (Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4 simulates the 
collagen self-assembly into a fibrous structure, which eventually triggers a hydrogel formation 
[159]. Similarly, α helical peptides [160], β sheet peptides [161], β hairpin peptides [162], 
amphiphilic peptides [163] and multi-domain peptides [164,165] can lead to self-assembled 
hydrogels based on the chirality and nature of the aminoacidic side chains. As a result, the 
supramolecular hydrogels may vary in their physico-chemical properties such as stiffness, porosity 
and degradation properties. 
The physico-chemical properties of hydrogel platforms play an important role in controlled delivery 
of bioactive factors or cells with a therapeutic potential. A recent study has shown the use of a 
three-dimensional, self-assembled type-I collagen microgel in modulating angiogenic responses of 
human mesenchymal stem cells [166]. Such ECM based microniches also help in promoting 
phenotypic changes by mimicking the signature matrix microenvironment of the predominant cell 
population in the tissue [167,168]. Design of self-assembling peptides using phage display with 
high affinity to growth factors have been utilized for spatio-temporal release of growth factors such 
as BMP-2 (YPVHPST) and TGF-B1 (LPLGNSH) for cartilage and bone regeneration [169]. 
Stimulus responsiveness property has also been incorporated in self-assembling hydrogels, where 
degradation is triggered in presence of an enzyme or reactive species as catalyst. The self-assembly 
of such multi-domain peptides allows greater control on fiber length and diameter, gelling and 
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viscoelastic properties due to its modular design. K(SL)3RG(SL)3K-GRGDS is one example of a 
MMP2 cleavage specific peptide which undergoes the proteolytic degradation by collagenase IV 
[164]. For drug delivery, peptide amphiphiles loaded with therapeutic drugs self-assemble into 
fibrous nanostructures that disassembles and releases the drug upon enzymatic phosphorylation of 
the serine residue [170]. However, in vivo it becomes increasingly challenging to predict the local 
concentration of reactive enzymes. Hence, peptide self-assembling strategies incorporating ester 
groups, which hydrolyze in a more controlled manner than enzymatic reactions are favourable 
[171].
Self-assembled hydrogels made from functional extracellular matrix components have the 
advantage of achieving better biological recognition in a 3D tissue like environments with high 
fidelity. But the complexity, lack of control of the self-assembly process and variation from batch to 
batch may affect reproducibity. However, a semi synthetic approach in designing peptide sequences 
known to influence a biological function such as differentiation, maintenance of stemness or 
influence cellular secretome can be easily fabricated or coupled to a polymeric framework to match 
the physical properties of the tissue. This approach will endorse the need for designing a customised 
3D hydrogel with tunable mechanical and biochemical features using functional recognition 
sequences. Another perspective which has been thoroughly investigated involves spherical 
microgels, that are an interesting bridging among macro-hydrogels and spherical microcarriers 
[156,172]. They can be defined as microscale hydrogels, offering a higher surface to volume ratio, 
compare to macroscale hydrogels. This unique feature enhances both microgels stability and their 
integration within the local tissue mass transport, by decreasing the bulk resistance [173,174]. 
In a size and structural complexity decreasing progression, soft self-assembling frameworks for 
protein delivery can be encompassed by catanionic vesicles, colloidal hollow structures, based on 
pairing of oppositely charged ionic amphiphiles. In detail, the above mentioned amphiphiles easily 
self-aggregate [175] into multi-walled vesicular structures [176]. Vesicles are of increasing interest 
in the biotechnological field [177,178], mimicking biological membranes and their 
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compartmentalization features [179]. Moreover, triggering factors for these structures involves 
salt/co-solutes addition, chain length and temperature, able to provide to multi-to-unilamellar 
transition and thus a controlled therapeutic release [180]. On the other side, liposomes offer another 
‘soft’ alternative for tunable compartmentalization and biological responsive protein delivery. 
Microspheres and hollow spheres are an additional tool for tailored delivery of proteins and growth 
factors, which have been extensively studied. Both synthetic (i.e. polyethyetylene glycol-PEG and 
polydimetylacrylamide-PDMA) and natural based polymers have been employed in their 
fabrication [181,182] Different strategies for their production were proposed, such as emulsion, 
sacrifical template coating, chemical binding. Furthermore, ECM mimicking motifs allow the 
specifi targeting of cellular proteins: this unique feature provide these reservoir systems with 
excellent performances and targeting properties, for growth factors delivery [183,184].
Still keep on decreasing the available protein vehicle systems, there is considerable interest for 
carbon nano-onion [148]. These multi-shell fullerene structures pertain unique physicochemical 
properties of, such as ultra-small size, large surface to mass ratio, high flexibility and capability to 
be complexed (either covalently or non-covalently) with bioactive molecules, including small 
proteins like enzyme binding moieties [148].
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Figure 6. Schematic representation recapitulating platforms for protein/growth factor delivery. 
Scaffold size is decreasing clockwise, from (A) to (F).
5. Synthetic therapeutics delivery
5.1 Challenges of small molecules in drug delivery
Despite in the last twenty years the main trend in pharmaceutical research was driven towards a 
growing interest in macromolecular therapeutics [185], most of the active ingredients still belongs 
to the class of small molecules under 500 Da. For instance, in cancer research, almost 75% of these 
therapeutics derive from synthetic sources [186]. The major issue of small molecule therapeutics is 
represented by the toxic side effects of high doses, due to an overall poor biodistribution and rapid 
clearance [187]. Moreover, when a low invasive and high patient friendly administration route is 
chosen, such as the oral approach, additional factors can influence and reduce the therapeutic 
efficacy of the majority of Active Pharmaceutical Ingredients (APIs) with poor solubility and low 
permeability in gastro-intestinal environment [188]. Besides solubility issues of hydrophobic 
compunds, a larger group of drugs are susceptible to several biochemical barriers, such as 
enzymatic attack, hydrolysis, degradation in the low gastric pH, unspecific endocytosis of the 
31
extended mucosa surface [189], pre-systemic metabolic pathways [190], intracellular 
biotrasformations [191] and plasma proteins complexation and recognition by the cells of the 
mononuclear phagocyte system [192].
Nowadays, the low bioavailability still represents a concrete issue: more than 90% of active 
compounds discovered and approved since 1995 belong either to class II or IV in the standard of 
Biopharmaceutical Classification System (BCS) [193]. Several strategies were developed to 
enhance both solubility and permeability of APIs. These approaches include the modification of 
both physical and chemical properties of the API [194]. The modification of physical characteristics 
is mainly focused on micronization techniques [195,196] reduction of crystal sizes, amorphization 
and stabilization of such solid dispersions [197,198]. Recently, further efforts have been paid to 
enhance specific organs and tissues targeting, while improving drug permeability on specific 
diseased cell targets. 
5.2 Lipid based- nanovesicles
As previously mentioned, lipid based nanovesicles (LNVs) are defined as spherical vesicles 
constituted by a bilayered lipid membrane. In a size-driven perspective, these colloidal carriers can 
be divided into small unilamellar vesicles (SUVs, with diameter <200 nm and single bilayer 
membrane), large unilamellar vesicles (LUVs, diameter ranging 200-1000 nm, single bilayer 
membrane), giant unilamellar vesicles (GUVs, diameter >1000 nm, single bilayer membrane), 
multilamellar vesicles (MLVs composed by concentric vesicles, or multiple concentric bilayers) 
and multi vesicular vesicles (MVVs, composed by multiple vesicles confined inside a larger one). 
Figure 7 groups the different types of nanovesicular systems, with increasing size characteristics. 
Since the first LNV proposed by Gregoriadis in 1974 [120], a large number of nanovesicicular 
systems were developed. Such an impressive success is due to their ability to incorporate functional 
biomacromolecules on the lipid bilayer, proposing as smart, flexible, stimuli responsive systems. 
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Key features of these colloidal carriers involve the API encapsulation efficiency (EE), the particle 
size distribution and the z potential.
Figure 7. Schematic representation of the main lipid based nanovesicular systems.
Over lipidic nanovesicles class, liposomes were the first discovered structures, composed by natural 
phospholipids membranes in the form of SUV and MLV. Nowadays, further in-depth researches 
explored the use of many synthetic phospholipids like phosphatidylglycerol, 
phosphatidylethanolamine, phosphatidylcholine and phosphatidylserine [199]. The first method 
developed for the encapsulation of hydrophilic compounds refers to the thin layer hydration (TLH), 
characterized by a very low EE due to the highly non-favoured partition of hydrophilic molecules 
inside the vesicle cavity versus the surrounding aqueous medium. Further methods involved the 
combination of TLH with other approached to enhance the EE of hydrophilic molecules: reiterated 
freeze–thaw (FT), reverse phase evaporation (REV) and dehydration–rehydration of empty vesicles 
(DRV).
The FT method allows the spontaneous MLVs disruption by the water ice crystals produced in the 
freezing process, leading to the fabrication of SUVs. The EE can be modulated by tuning the FT 
cycle rate, the aqueous solute and lipid concentrations. Additional extrusion steps after FT have 
shown to improve the size distribution, such as the encapsulation of the hydrophilic drug itopride in 
liposomes [200]. On the other hand, multiple FT cycles can increase liposome diameter and 
33
polydispersity, when liposome components are highly susceptible to salt concentration (i.e. egg 
phosphatidylcholine) [201].
Reverse phase evaporation method (REV) is another approach to encapsulate small hydrophilic 
drugs. Therein, the lipids are dissolved in an organic phase and further incorporated in an aqueous 
phase with the drug. The obtained emulsion is subsequently treated with evaporation-hydration 
cycles, leading to the formation of liposomes, mainly LUVs with large EE. For example, the 
addition of the REV step to TLH introduced an EE increase in the case of sumatriptan succinate 
[202]. Conversely the utilization of REV can result in a decrease of hydrophobic drugs 
encapsulation efficiency, compared to TFH, as in the case of acetazolamide, inside multilamellar 
vesicles [203] and ketoprofen-hydroxypropyl-β-cyclodextrin complexes included into large 
unilamellar vesicles [204]. Liposomal vesicles can be fabricated by means of a dehydration–
rehydration method (DRV), adding a buffer to the thin film and further lyophilize. The solid pellet 
is then rehydrated with the drug solution. Compared to conventional TFH, DRV produced a high 
drug/lipid ratio in the case of vancomycin [205], with an impressive increase of EE (30 and 130 
fold), for both non-decorated and pegylated liposomes, respectively. Recent reviews discussed 
innovative methods for liposomes fabrication [206-208], including microfluidics [209,210], 
compressed/supercritical fluids for the incorporation of both hydrophilic and lipophilic drugs into 
the vesicles [211,212].
A large variety of liposomal formulations was developed by incorporating one or more multitasking 
ligands within the vesicle membrane. Liposomes can exert a passive targeting by enhancing the 
permeability retention time [213] or by depletion of macrophages, as shown in the case of the 
hydrophobic drug amphotericin B [214]. On the other hand, active targeting features can involve 
the binding mechanisms of liposomes towards bioactive receptors, such as antibody conjugates 
[215] or permeation enhancers, like cell-penetrating peptides (CPPs) [216]. Stimuli-responsiveness 
is an attractive perspective for specifically triggered drug release towards liposomes, aiming to 
reduce the side effects of unspecific targeting through a dual action. In the first instance, by 
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targeting the lower pH inside the endosome; secondly, while providing for conformational changes 
of dioleylphosphoethanolamine (DOPE) and cholesterylhemisuccinate, the therapeutic cargo can be 
released in the cytoplasm [217]. At present, doxorubicin is one of the most studied drugs for 
liposomal triggered-release, with a thermosensitive formulaton, ThermoDox®, in clinical trials. 
Other liposomal formulations with small bioactive molecules are available in the market, with good 
encapsulation efficiency. Nevertheless targeted formulations or stimuli-responsive liposomes are 
still challenging at a research stage.
The main reason for such a limited transfer of liposomal formulation into the bipharmaceutical 
market relies on the drawback of their low physico-chemical stability, due to the intrinsic poor 
aqueous solubility of phospholipids, which tend to aggregate into bigger clusters [218]. As a 
consequence, liposome suspensions are usually lyophilized and stored as dry products [219]. 
5.3 Non-liposomal nanovesicles
The limited efficacy of liposomes broadens research horizons towards employing lipids in 
combination with alternative self-assembling materials, such as surfactants [220,221], polymers 
[222] and peptides [223]. 
Non-liposomal nanovesicles can be classified according to the alternative component versus 
phospholipid: niosomes, sphingosomes, pharmacosomes and quatsomes.
Niosomes are prepared by hydrating a mixture of lipids with non-ionic surfactants, such as alkyl 
ethers, alkylesters alkylamides, fatty acids and amino acids. Niosomes are able to encapsulate both 
hydrophilic and hydrophobic drugs. The use of cholesterol as lipid component leads to a more rigid 
and less leaky bilayers, which makes it particularly suitable for small drugs such as calcein [224] or 
poorly soluble beclomethasone dipropionate [221]. Niosomes exhibit an overall short-term stability, 
which strongly depends on the additional membrane components [225]. 
Sphingosomes are composed by natural or synthetic sphingolipids, which form nanovesicles in the 
form of SUVs and LUVs. Compared to niosomes, they show an enhanced stability, as well as an 
improved resistance against hydrolysis, compared to liposomes. A promising application of 
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sphingosomes was found in the encapsulation of alchaloids like vinorelbine [226].
In pharmacosomes, normal phospholipids are replaced by lipids covalently bonded to the API to be 
delivered. Pharmacosomes demonstrated higher encapsulation efficiency than liposomes [227].
Quatsomes are unilamellar nanovesicles composed by quaternary ammonium surfactants and sterols 
(e. g. cholesterol and β-sitosterol) [228]. Several surfactants were utilized so far: cetrimonium 
bromide (CTAB), myristalkonium chloride (MKC) and cetylpyridinium chloride (CPC). Their 
unilamellar and homogeneous morphology proposes these nanovesicles as excellent candidates for 
stable functionalization aimed to passive targeting [212]. Their key features consist of their very 
low size, good dispersion, as well as the remarkable and long-term stability [229]. 
Conventional fabrication methods like TFH were combined with size reducing post formation steps. 
Extensively studied examples are ultrasound sonication, proposed for liposomal encapsulation of 
anticancer drugs [230], extrusion reduced polydispersity and size of niosomes loaded with tretinoin 
[231] or high-pressure homogenization with a uniform dispersion of SUVs containing the poorly 
soluble drug fenofibrate [232]. The most novel technologies are based on compressed fluids (CFs) 
[212,233], microfluidics [209,230] and freeze-drying of emulsions [234]. In compressed fluid 
technology (CFs), the gas is rapidly pressurized, which modulate the solvent density. Fast density 
variations are more significant when there is a phase transition crossing the critical point. The 
broadest fluid employed in this field is carbon dioxide (CO2) thanks to its mild critical conditions 
(Pc= 74 bar, Tc=30.95 ºC), which allow the application to thermosensitive compounds. Within this 
group, it is worth to mention the Depressurization of Expanded Liquid Organic Solution-
SUSPension (DELOS SUSP) [212,229] and DESAM (Depressurization of an Expanded Solution 
into Aqueous Media) [235]. 
Another unconventional method for nanovesicles production is based on the freeze-drying of 
emulsions. Herein, the hydrophilic components (i. e. drug and or cryoprotectant) and hydrophobic 
components (i. e. drugs and lipids) are dissolved respectively in water and organic phases, leading 
to an emulsion by mixing. The emulsion is freeze-dried and the solid pellet is resuspended prior its 
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use. Several small molecule drugs including both hydrophobic (e. g. flurbiprofen) and hydrophilic 
(e. g. paeoniflorin) and amphiphilic (e. g. barberin) APIs were encorporated into liposomal SUVs 
[234].
The new generation of nanovesicles shows complementary features compared to liposomes, 
overcoming most of their drawbacks in terms of formulation stabililty, easy technology and cost-
effectiveness. Besides liposomes have already shown a complete potential as nanocarriers, non-
liposomal L-NVs propose as promising frontiers in the near future, from the lab bench to clinical 
practice. 
6. Nanocarriers for bioimaging and diagnostic
High-resolution cellular and tissue imaging is a highly interdisciplinary field, merging expertise in 
materials chemistry, nanotechnology, biology, physics and medicine. In this context, optical and 
fluorescent imaging is a research branch of increasing interest because is non-invasive, involves the 
use of visible, ultraviolet and infrared light decreasing the exposure to harmful radiation, and can 
produce images of organs, soft tissue and cells both in vitro and in vivo. 
Applications of fluorescent carriers span from in vitro biologically relevant processes associated 
with diseases and aberrant situation (i.e. cancers) to in vivo imaging of biological pathways. Thus, 
the main characteristics for a colloidal platform involve highly tunable size and surface, ability to 
further target the cell surface with enzyme-binding motifs penetration and imaging capabilities. In 
the past years fluorescent carriers to be applied as optical imaging tools have been developed both 
for the localization of specialized nanoparticles in the cells and for diagnostic applications. The 
cellular uptake of nanoparticles and the compartmentalization of the latter in a specific organ or 
tissue or inside the cell can be achieved by this method. Moreover imaging as a non-invasive 
technique for live study event at a molecular level and as diagnostic tool which can identify 
abnormalities on patients before or after the development of the disease is needed. 
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One of the main strategies to enhance bio-imaging rely on the development of imaging probes for 
the biologically relevant near-infra red (NIR) and far-red region, where tissue exhibit minimal 
absorbance [236].  Therefore the development of new organic dies molecule emitting in the far-red 
and NIR region [237].  is increasing thanks to their ability to reduce the tissue auto-fluorescence, 
allowing a high resolution imaging and a deeper tissue penetration. 
Carbon Nano Materials (CNMs) have arisen great interest for biomedical application due to their 
biocompatibility, low toxicity, small size, and large surface area. Surface functionalization on these 
materials is possible and well explored, usually through chemical reaction directly with the sp2 
carbon atoms present on the material surface. This allows their surface modification to make CNMs 
soluble in aqueous environments and biocompatible, besides readily internalized by cells. On the 
other hand this chemically controlled surface functionalization both by covalent and noncovalent 
approach (e.g π-π stacking), allowed chemist to create specialized nanoparticle specific for 
bioimaging. Moreover, some CNMs such as single walled carbon nanotubes (SWCNTs) [238], 
carbon dots (CDs) [239].  and graphene, can also act as imaging agents themselves, due to their 
intrinsic optical properties [240]. 
Multi-shell fullerenes, known as carbon nano-onions (CNOs), have recently gathered great interest 
among researchers and have been successfully applied in a variety of different fields of application 
such as energy storage [241,242], catalysis [243], supercapacitors  [244] and imaging [245].  
CNOs are attractive platforms for imaging, diagnostic and therapeutic applications, thanks to their 
small size. Moreover, their surface can be chemically modified modulating cell penetration and cell 
recognition respectively [148]. Recent reports showed that fluorescently labelled CNOs, with an 
average of 5 nm, exhibit weak inflammatory potential and a low cytotoxicity [246]. They are 
readily internalized by cancer cells and deposited in the lysosomes [247,248]. Toxicological studies 
were conducted on fluorescein-functionalized CNOs both in vitro and in vivo. A comparison among 
the above mentioned functionalized CNOs and functionalized carbon nanotubes (CNTs) in terms of 
cytotoxicity and immunomodulatory properties demonstrated that CNOs exhibit efficient cellular 
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uptake and reveal a bright fluorescence signal [246].  These biologically relevant features proposed 
CNOs at the forefront for biomedical applications. Moreover, in vivo studies on zebrafish (Danio 
Rerio) in the development stage, confirmed their ecocompatibility and homogenous distribution in a 
vertebrate model system, exhibiting excellent performances as biomedical probes [249].   An 
example of multi-functionalized CNOs (f-CNOs) as targeted delivery system have been reported, 
where CNOs were surface functionalized with fluorescein and folic acid moieties for both imaging 
and targeting of cancer cells [248].  The f-CNOs showed a bright fluorescence and a selective and 
rapid internalization in cancer cells (HeLa and KB cells) without toxicity. The f-CNOs were 
localized into specific cell compartments using a correlative approach with confocal and 
transmission electron microscopy [248].
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Figure 8.  High resolution TEM image (a) and AFM topograph (b) of pristine CNOs. Confocal 
microscopy of C57BL/6 BMDCs incubated in the presence of fluorescein-CNOs (green), stained 
with wheat germ agglutinin-Alexa Fluor594 (red) and nuclei stain Hoescht (blue) (c). a) b) and c) 
are reproduced from [246], Copyright 2013 Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced 
with permission. (d) Representative optical images of zebrafish exposed to BODIPY-CNOs (green). 
Maximum intensity projections of the superior part (left) and tail (right) (Scale bars, 100 μm). 
Reprinted with permission from [249]. Copyright 2016 Nature Publishing Group.
Fullerene C60 is a symmetrical sphere made of carbon atoms with a diameter of 1 nm, which has 
been widely used for biomedical application. Nevertheless the increasing interest on other CNMs 
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such as CNTs and graphene, several examples of fullerene used for drug delivery and bio-imaging 
are present in literature. For examples, biocompatible color-tunable photoluminescent fullerene 
nanomaterials were synthetized by conjugating C60 particles with tetraethylene glycol (TEG) 
molecules [250].  Their high quantum yield and water solubility make them suitable for bio-
imaging application. Recently a biocompatible and water-soluble mesoporous silica nanoparticle 
(MSN) coated with fullerene molecules was reported for the drug release of doxorubicin (DOX) in 
a mild acidic environment [251].  Furthermore, C60-modified MSN showed a green fluorescence of 
peculiar interest for cellular imaging. 
Several carbon nanomaterials are known to emit fluorescence light upon photo-excitation [240].  
The leading examples on CNMs with intrinsic optical properties are semiconducting SWCNTs, 
which show a structure dependent fluorescence in the biologically important 1300-1400 nm near-
infrared window (NIR-IIa window). 
The live imaging of mouse cerebral vasculature using SWCNTs was previously achieved without 
the necessity of craniotomy, cranial windows and skull thinning techniques which are usually 
required [252].  The reduced short-wavelength photon scattering in the NIR-IIa window, allowed an 
improved imaging resolution to a depth of  > 2 mm using three-dimensional in vivo imaging 
through confocal or two-photon techniques. Carbon nanotubes offer also a promising tool as drug 
delivery system, due to their spectroscopic properties and easy surface functionalization. Targeted 
drug delivery system have been reported with CNTs where a drug is loaded on their surface, either 
covalently or by absorption, together with a ligand to facilitate the targeting of selective cancer 
cells. An example is the loading of DOX on SWCNTs through π-π stacking which is feasible due to 
the aromatic moiety of the drug  [253,254]. The DOX was loaded on a high ratio on the SWCNTs 
surface, and the drug was readily released within the acidic tumor microenvironment.  Similarly to 
the adsorption of an aromatic drug molecule, an aromatic organic dye molecule can be absorbed on 
the surface of CNMs. For instance boron dipyrromethene (BODIPY)–pyrene/CNTs [255] and 
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pyrene–BODIPY/CNOs [256] hybrids have been reported as imaging probes, where pyrene is used 
as an anchoring group. 
Similarly to SWCNTs, CDs are biocompatible carbonaceous nanoparticles with intrinsic 
fluorescence easing the inconvenient of functionalizing these nano-probes with small organic 
fluorophore molecules. On the other hand their surface can be chemically modified allowing their 
functionalization with a therapeutic agent and a targeted ligand to apply them as a targeted drug 
delivery system. With a diameter below 10 nm and their low toxicity, they are widely used for 
biomedical applications. Favorable characteristic of CDs are their size- and excitation wavelength- 
dependent photoluminescence (PL) behavior, high stability and resistance to photo bleaching.  
Biocompatibility studies and bio distribution of CDs have been explored on zebrafish as an 
vertebrate model system, proving their compatibility with life and validating their application as 
multi-color imaging probe   [257].
CDs have a tunable emission wavelength, depending on the excitation wavelength, and their 
reported fluorescence wide-ranged from NIR [258], to visible [239], to deep ultraviolet [259].  
Their versatile optical properties allowed them to be employed in several biomedical applications, 
from in vivo imaging to drug delivery. 
Furthermore, fullerene [260] and CNTs [261]  have been proposed for the  development of  new 
MRI contrast agents. In detail, fullerenes can encapsulate gadolinium, decreasing its toxicity. An 
example is represented by gadolinium (Gd)-containing C80 endohedrals (Trimetaspheres™,TMS, 
Gd3N@C80) which was used as an atherosclerotic targeting contrast agents (ATCA) for 
cardiovascular magnetic resonance (CMR) [262].  Similarly gadolinium-functionalized MWCNTs 
as contrast agent for MRI cell labelling and tracking was recently reported [261].   
Multi-modal molecular imaging technique, which is the synergistic combination of two or more 
detection techniques [263], is also used. Examples of the ‘‘dual active’’ approach include the 
development of nanoparticles combining fluorescence and magnetic resonance imaging as they 
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merge effectively the high sensitivity of the fluorescence phenomenon with the high spatial 
resolution of MRI. 
CNMs are quite promising for biomedical applications, as imaging tools, due to their small size, 
biocompatibility and optical characteristics. Besides their intrinsic optical properties and resistance 
to photo bleaching, their quantum yield is lower than small organic molecule. However a 
synergistic combination strategy of synthetic dyes and CNMs hybrids can lead to extreme powerful 
imaging probe for both in vitro and in vivo applications.
7. Conclusions and future outlook
Self-assembly mechanisms mimick biological processes by recapitulating morphological structure 
and organization of native tissues. Overall, all strategies discussed herein, explain the use of 
different colloidal systems to be employed for a tailored bioactive molecule depot. These strategies 
depend on the hierarchical and functional complex stuctures involved, including the target living 
tissues. The functional design of the constructs is encoded by the properties of the fundamental 
units. The tunable characteristics of the systems therefore generated, can ensure precise release of 
bioactive factors or induce a conformational change at the tissue interface. Thus, controlled 
fabrication and selection of colloidal-based scaffolds can help in rapid development of cost-
effective engineered solutions for clinical use. 
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Highlights
Tailored bioactive molecule delivery can be targeted towards several colloidal structures, such as: 
• Hydrogels
• Microgels
• Liposomes
• Surfactant self-assembly
• Covalently functionalized colloidal structures
• Polymers assembly features
• Carbon nano materials
• Polyplexes
• Lipoplexes
• Hollow spheres
